{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:18:27Z","timestamp":1791328707291,"version":"4.3.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T00:00:00Z","timestamp":1252368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1741-7015-7-44","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T19:46:55Z","timestamp":1252439215000},"source":"Crossref","is-referenced-by-count":103,"title":["Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)"],"prefix":"10.1186","volume":"7","author":[{"given":"Walter JFM","family":"van der Velden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs MP","family":"van Iersel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole MA","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Peter","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,8]]},"reference":[{"key":"222_CR1","first-page":"605","volume":"17","author":"NM Blijlevens","year":"2005","unstructured":"Blijlevens NM: Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol. 2005, 17: 605-610.","journal-title":"Curr Opin Oncol"},{"key":"222_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00520-006-0176-9","volume":"15","author":"M Vera-Llonch","year":"2007","unstructured":"Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S: Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007, 15: 491-496. 10.1007\/s00520-006-0176-9.","journal-title":"Support Care Cancer"},{"key":"222_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/sj.bmt.1704966","volume":"35","author":"JJ Auletta","year":"2005","unstructured":"Auletta JJ, Lazarus HM: Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant. 2005, 35: 835-857. 10.1038\/sj.bmt.1704966.","journal-title":"Bone Marrow Transplant"},{"key":"222_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","volume":"36","author":"A Gratwohl","year":"2005","unstructured":"Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C: Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005, 36: 757-769. 10.1038\/sj.bmt.1705140.","journal-title":"Bone Marrow Transplant"},{"key":"222_CR5","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/sj.leu.2402946","volume":"17","author":"R Schots","year":"2003","unstructured":"Schots R, Kaufman L, Van RI, Ben OT, De WM, Van CB, Demanet C: Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003, 17: 1150-1156. 10.1038\/sj.leu.2402946.","journal-title":"Leukemia"},{"key":"222_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(06)70599-0","volume":"6","author":"A Robicsek","year":"2006","unstructured":"Robicsek A, Jacoby GA, Hooper DC: The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006, 6: 629-640. 10.1016\/S1473-3099(06)70599-0.","journal-title":"Lancet Infect Dis"},{"key":"222_CR7","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","volume":"5","author":"E Snelders","year":"2008","unstructured":"Snelders E, Lee van der HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE: Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008, 5: e219-10.1371\/journal.pmed.0050219.","journal-title":"PLoS Med"},{"key":"222_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMp0804651","volume":"360","author":"CA Arias","year":"2009","unstructured":"Arias CA, Murray BE: Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N Engl J Med. 2009, 360: 439-443. 10.1056\/NEJMp0804651.","journal-title":"N Engl J Med"},{"key":"222_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s00018-007-6475-6","volume":"64","author":"N Mookherjee","year":"2007","unstructured":"Mookherjee N, Hancock RE: Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci. 2007, 64: 922-933. 10.1007\/s00018-007-6475-6.","journal-title":"Cell Mol Life Sci"},{"key":"222_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/1568005024605855","volume":"2","author":"RE Hancock","year":"2002","unstructured":"Hancock RE, Patrzykat A: Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord. 2002, 2: 79-83. 10.2174\/1568005024605855.","journal-title":"Curr Drug Targets Infect Disord"},{"key":"222_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M: Antimicrobial peptides of multicellular organisms. Nature. 2002, 415: 389-95. 10.1038\/415389a.","journal-title":"Nature"},{"key":"222_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1084\/jem.130.3.643","volume":"130","author":"PL Masson","year":"1969","unstructured":"Masson PL, Heremans JF, Schonne E: Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med. 1969, 130: 643-658. 10.1084\/jem.130.3.643.","journal-title":"J Exp Med"},{"key":"222_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/0009-8981(66)90004-0","volume":"14","author":"PL Masson","year":"1966","unstructured":"Masson PL: An iron-binding protein common to many external secretions. Clinica Chimica Acta. 1966, 14: 735-739. 10.1016\/0009-8981(66)90004-0.","journal-title":"Clinica Chimica Acta"},{"key":"222_CR14","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00018-005-5370-2","volume":"62","author":"D Legrand","year":"2005","unstructured":"Legrand D, Elass E, Carpentier M, Mazurier J: Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005, 62: 2549-2559. 10.1007\/s00018-005-5370-2.","journal-title":"Cell Mol Life Sci"},{"key":"222_CR15","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/s00018-005-5373-z","volume":"62","author":"JL Gifford","year":"2005","unstructured":"Gifford JL, Hunter HN, Vogel HJ: Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci. 2005, 62: 2588-2598. 10.1007\/s00018-005-5373-z.","journal-title":"Cell Mol Life Sci"},{"key":"222_CR16","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1007\/s00018-005-5372-0","volume":"62","author":"P Valenti","year":"2005","unstructured":"Valenti P, Antonini G: Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci. 2005, 62: 2576-2587. 10.1007\/s00018-005-5372-0.","journal-title":"Cell Mol Life Sci"},{"key":"222_CR17","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1007\/s00018-005-5369-8","volume":"62","author":"PP Ward","year":"2005","unstructured":"Ward PP, Paz E, Conneely OM: Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci. 2005, 62: 2540-2548. 10.1007\/s00018-005-5369-8.","journal-title":"Cell Mol Life Sci"},{"key":"222_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0009-8981(91)90262-B","volume":"202","author":"T Suzuki","year":"1991","unstructured":"Suzuki T, Takizawa-Mizuno M, Yazaki M, Wada Y, Asai K, Kato T: Plasma lactoferrin levels after bone marrow transplantation monitored by a two-site enzyme immunoassay. Clin Chim Acta. 1991, 202: 111-117. 10.1016\/0009-8981(91)90262-B.","journal-title":"Clin Chim Acta"},{"key":"222_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1399-3062.2007.00260.x","volume":"10","author":"WJFM van der Velden","year":"2008","unstructured":"Velden van der WJFM, Blijlevens NM, Donnelly JP: The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation. Transpl Infect Dis. 2008, 10: 80-89. 10.1111\/j.1399-3062.2007.00260.x.","journal-title":"Transpl Infect Dis"},{"key":"222_CR20","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1128\/AAC.49.6.2438-2444.2005","volume":"49","author":"C Faber","year":"2005","unstructured":"Faber C, Stallmann HP, Lyaruu DM, Joosten U, von EC, van Nieuw AA, Wuisman PI: Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother. 2005, 49: 2438-2444. 10.1128\/AAC.49.6.2438-2444.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"222_CR21","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1128\/AAC.44.12.3257-3263.2000","volume":"44","author":"A Lupetti","year":"2000","unstructured":"Lupetti A, Paulusma-Annema A, Welling MM, Senesi S, Van Dissel JT, Nibbering PH: Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother. 2000, 44: 3257-3263. 10.1128\/AAC.44.12.3257-3263.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"222_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1086\/522427","volume":"196","author":"A Lupetti","year":"2007","unstructured":"Lupetti A, Brouwer CP, Bogaards SJ, Welling MM, de HE, Campa M, Van Dissel JT, Friesen RH, Nibbering PH: Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007, 196: 1416-1424. 10.1086\/522427.","journal-title":"J Infect Dis"},{"key":"222_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jac\/dkh346","volume":"54","author":"HP Stallmann","year":"2004","unstructured":"Stallmann HP, Faber C, Bronckers AL, Nieuw Amerongen AV, Wuisman PI: Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J Antimicrob Chemother. 2004, 54: 472-476. 10.1093\/jac\/dkh346.","journal-title":"J Antimicrob Chemother"},{"key":"222_CR24","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1128\/AAC.48.12.4919-4921.2004","volume":"48","author":"L Dijkshoorn","year":"2004","unstructured":"Dijkshoorn L, Brouwer CP, Bogaards SJ, Nemec A, Broek van den PJ, Nibbering PH: The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004, 48: 4919-4921. 10.1128\/AAC.48.12.4919-4921.2004.","journal-title":"Antimicrob Agents Chemother"},{"key":"222_CR25","first-page":"25691","volume":"62","author":"World Health Organization","year":"1997","unstructured":"World Health Organization: World Health Organization International Conference on Harmonization. Topic E6: Guidelines for Good Clincial Practice. US Federal Register. 1997, 62: 25691-25709.","journal-title":"Topic E6: Guidelines for Good Clincial Practice. US Federal Register"},{"key":"222_CR26","unstructured":"Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3.0. [ http:\/\/ctep.cancer.gov ]"},{"key":"222_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00277-005-0048-2","volume":"85","author":"S Neuburger","year":"2006","unstructured":"Neuburger S, Maschmeyer G: Update on management of infections in cancer and stem cell transplant patients. Ann Hematol. 2006, 85: 345-356. 10.1007\/s00277-005-0048-2.","journal-title":"Ann Hematol"},{"key":"222_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1042\/bj3280145","volume":"328","author":"PH van Berkel","year":"1997","unstructured":"van Berkel PH, Geerts ME, van Veen HA, Mericskay M, de Boer HA, Nuijens JH: N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem J. 1997, 328: 145-151.","journal-title":"Biochem J"},{"key":"222_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1042\/bj3270841","volume":"327","author":"D Legrand","year":"1997","unstructured":"Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, Nuijens JH, Spik G: The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. Biochem J. 1997, 327: 841-846.","journal-title":"Biochem J"},{"key":"222_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-4615-2548-6_8","volume":"357","author":"RT Ellison III","year":"1994","unstructured":"Ellison RT: The effects of lactoferrin on Gram-negative bacteria. Adv Exp Med Biol. 1994, 357: 71-90.","journal-title":"Adv Exp Med Biol"},{"key":"222_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1348-0421.2003.tb02783.x","volume":"47","author":"H Wakabayashi","year":"2003","unstructured":"Wakabayashi H, Takakura N, Teraguchi S, Tamura Y: Lactoferrin feeding augments peritoneal macrophage activities in mice intraperitoneally injected with inactivated Candida albicans. Microbiol Immunol. 2003, 47: 37-43.","journal-title":"Microbiol Immunol"},{"key":"222_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/cimm.1997.1246","volume":"187","author":"H Miyauchi","year":"1998","unstructured":"Miyauchi H, Hashimoto S, Nakajima M, Shinoda I, Fukuwatari Y, Hayasawa H: Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain. Cell Immunol. 1998, 187: 34-37. 10.1006\/cimm.1997.1246.","journal-title":"Cell Immunol"},{"key":"222_CR33","first-page":"63","volume":"35","author":"A Szuster-Ciesielska","year":"1995","unstructured":"Szuster-Ciesielska A, Kaminska T, Kandefer-Szerszen M: Phagocytosis-enhancing effect of lactoferrin on bovine peripheral blood monocytes in vitro and in vivo. Arch Vet Pol. 1995, 35: 63-71.","journal-title":"Arch Vet Pol"},{"key":"222_CR34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1139\/o06-045","volume":"84","author":"D Legrand","year":"2006","unstructured":"Legrand D, Elass E, Carpentier M, Mazurier J: Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol. 2006, 84: 282-290. 10.1139\/O06-045.","journal-title":"Biochem Cell Biol"},{"key":"222_CR35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/IAI.66.2.486-491.1998","volume":"66","author":"E Elass-Rochard","year":"1998","unstructured":"Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, Mazurier J, Spik G: Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun. 1998, 66: 486-491.","journal-title":"Infect Immun"},{"key":"222_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0008-8749(03)00006-6","volume":"220","author":"L Haversen","year":"2002","unstructured":"Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I: Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol. 2002, 220: 83-95. 10.1016\/S0008-8749(03)00006-6.","journal-title":"Cell Immunol"},{"key":"222_CR37","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1128\/IAI.69.3.1469-1476.2001","volume":"69","author":"PH Nibbering","year":"2001","unstructured":"Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, Nuijens JH: Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun. 2001, 69: 1469-1476. 10.1128\/IAI.69.3.1469-1476.2001.","journal-title":"Infect Immun"},{"key":"222_CR38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1128\/AAC.47.1.262-267.2003","volume":"47","author":"A Lupetti","year":"2003","unstructured":"Lupetti A, Paulusma-Annema A, Welling MM, Dogterom-Ballering H, Brouwer CP, Senesi S, Van Dissel JT, Nibbering PH: Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob Agents Chemother. 2003, 47: 262-267. 10.1128\/AAC.47.1.262-267.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"222_CR39","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.peptides.2005.05.014","volume":"26","author":"HP Stallmann","year":"2005","unstructured":"Stallmann HP, Faber C, Bronckers AL, de Blieck-Hogervorst JM, Brouwer CP, Amerongen AV, Wuisman PI: Histatin and lactoferrin derived peptides: antimicrobial properties and effects on mammalian cells. Peptides. 2005, 26: 2355-2359. 10.1016\/j.peptides.2005.05.014.","journal-title":"Peptides"},{"key":"222_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrmicro2095","volume":"7","author":"MN Melo","year":"2009","unstructured":"Melo MN, Ferre R, Castanho MA: Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat Rev Microbiol. 2009, 7: 245-250. 10.1038\/nrmicro2095.","journal-title":"Nat Rev Microbiol"},{"key":"222_CR41","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975, 36: 842-854. 10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U.","journal-title":"Cancer"},{"key":"222_CR42","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998, 102: 1115-1123. 10.1046\/j.1365-2141.1998.00930.x.","journal-title":"Br J Haematol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-7-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-7-44\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-7-44","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T02:07:43Z","timestamp":1590113263000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-7-44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,8]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-7-44","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,8]]},"article-number":"44"}}